Loading data for FMS — first visit, this takes a few seconds.

アラート

Fresenius Medical Care AG (FMS)

NYSE: FMS · リアルタイム株価 · USD

23.84

+0.28 (1.19%)

終値時点： Aug 19, 2026, 12:06 PM

23.84

+0.00%

時間外: 5:05 PM

1.19% (1D)

買気配	23.81
時価総額	12.69B
売上高（TTM）	19.43B
純利益（TTM）	937.78M
ベータ	0.84
EPS（TTM）	1.92
PER（TTM）	12.42
予想PER	6.55
PBR（TTM）	0.87
PSR（TTM）	0.65
Earnings Date	Nov 3, 2026

売気配	23.82
出来高	383,978
平均出来高（20日）	732,358
始値	23.71
前日終値	23.56
当日レンジ	23.75 - 24.04
52週レンジ	20.02 - 27.64
アナリスト	n/a
目標株価	n/a
配当	$0.87 (3.7%)
権利落ち日	2026年5月22日

FMSについて

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient'...

[続きを読む]

業種 Medical Care Facilities

セクター Healthcare

IPO日 Sep 17, 1996

従業員数 107,226

上場取引所 NYSE

ティッカー FMS

ウェブサイト https://www.freseniusmedicalcare.com

企業情報の全文

業績

2025年のFresenius Medical Careの売上高は19.63Bで、前年の19.34Bから1.51%の増加でした。利益は978.37Mで、81.88%の増加でした。

財務諸表

決算サプライズ

Fresenius Medical CareはAug 3, 2026に四半期決算を発表しました：

売上高は n/a で、予想を下回りました $0, うち -100.00% の前年比減少.

EPSは 0.56 で、予想を上回りました 0.06, うち 21.74% の前年比増加にあたります.

次回決算発表

Fresenius Medical Care AGの決算発表予定日は Nov 3, 2026, 取引時間中の予定です。
アナリストの売上高予想は ... アップグレード

ニュース

1週間前 · Motley Fool

Fresenius Medical Care (FMS) Q2 2026 Earnings Call Transcript

U.S. referral execution gap offset by strong margin expansion and transformation savings.

2週間前 · Zacks

FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand

FMS posts 28% EPS growth as Care Delivery profitability and margin gains offset a quarterly revenue miss and weaker US treatment volumes.

2週間前 · Simply Wall St.

Fresenius Medical Care (XTRA:FME) Expands BEACON US To Build Its Case For HVHDF

Fresenius Medical Care is expanding its BEACON-US clinical initiative to build real-world evidence for high-volume hemodiafiltration therapy in the U.S. The program evaluates the 5008X CAREsystem and ...

2週間前 · Simply Wall St.

Fresenius Medical Care (XTRA:FME) Stock Looks Like A Bargain Despite Weak Returns

Fresenius Medical Care stock has recovered modestly in the short term yet is still down about 30% over the past five years, while recent valuation checks suggest the market may be pricing it on the ch...

2週間前 · Simply Wall St.

Is Fresenius Medical Care (XTRA:FME) Undervalued Following Its New CEO Appointment?

Fresenius Medical Care (XTRA:FME) has drawn fresh attention after the Supervisory Board appointed Cassie McLean as Management Board member and Chief Executive Officer of the Care Delivery segment, res...

2ページ中1ページ

Fresenius Medical Care AG (FMS)